AlphaCrest Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

AlphaCrest Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,054	Closed	-$1.55M	–	1040
2022 Q3	$1.55M	Sell	3,054 -1,006	-25%	-$563K	0.09%	340
2022 Q2	$2.21M	Buy	4,060 +2,073	+104%	+$1.14M	0.11%	275
2022 Q1	$1.17M	Sell	1,987 -3,073	-61%	-$1.77M	0.07%	470
2021 Q4	$3.38M	Buy	5,060 +1,894	+60%	+$1.18M	0.13%	185
2021 Q3	$1.81M	Sell	3,166 -387	-11%	-$212K	0.09%	355
2021 Q2	$1.79M	Sell	3,553 -13,933	-80%	-$6.57M	0.08%	398
2021 Q1	$7.98M	Buy	17,486 +16,108	+1,169%	+$7.69M	0.44%	27
2020 Q4	$642K	Buy	+1,378	New	+$646K	0.05%	513
2020 Q3	–	Sell	-1,312	Closed	-$475K	–	1197
2020 Q2	$475K	Sell	1,312 -11,262	-90%	-$3.77M	0.08%	410
2020 Q1	$3.57M	Buy	12,574 +4,530	+56%	+$1.43M	0.43%	11
2019 Q4	$2.61M	Buy	8,044 +1,599	+25%	+$485K	0.21%	79
2019 Q3	$1.88M	Sell	6,445 -697	-10%	-$200K	0.11%	259
2019 Q2	$2.1M	Buy	+7,142	New	+$1.97M	0.18%	143
2019 Q1	–	Sell	-5,878	Closed	-$1.31M	–	956
2018 Q4	$1.31M	Buy	+5,878	New	+$1.38M	0.39%	32

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's TMO Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Thermo Fisher Scientific (TMO) in Q4 2022, closing a stake of 3,054 shares — an estimated $1.55M sold.

AlphaCrest Capital Management first reported a position in TMO in Q4 2018 and held it in 14 quarters. The position peaked at $7.98M in Q1 2021. 2,374 funds tracked by Wall St. Rank hold TMO as of Q4 2022.

AlphaCrest Capital Management reported no remaining Thermo Fisher Scientific position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 3,054 Thermo Fisher Scientific shares in Q4 2022, an estimated $1.55M.
AlphaCrest Capital Management first reported a position in Thermo Fisher Scientific in Q4 2018 and held it in 14 quarters.
AlphaCrest Capital Management's Thermo Fisher Scientific position peaked at $7.98M in Q1 2021.
2,374 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.